[Update: Neuromuscular Blockade during General Anesthesia].

Update: Muskelrelaxierung in der Anästhesie.

Journal

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
ISSN: 1439-1074
Titre abrégé: Anasthesiol Intensivmed Notfallmed Schmerzther
Pays: Germany
ID NLM: 9109478

Informations de publication

Date de publication:
Aug 2024
Historique:
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 28 8 2024
Statut: ppublish

Résumé

The correct use of muscle relaxants and neuromuscular monitoring during anesthesia has been subject of controversial discussions for decades. Particularly important in clinical practice are identification and management of residual neuromuscular blockages and avoidance of associated complications. Despite the differences in the molecular mechanisms of action between depolarizing and non-depolarizing muscle relaxants the blockade of the postsynaptic nicotinic acetylcholine receptor remains a common ending pathway. Due to its unfavorable side effect profile, succinylcholine should only be used in justified exceptional cases. The use of muscle relaxants generally reduces the complication rate in airway management. However, even the single use of muscle relaxants increases the likelihood of postoperative pulmonary complications. These complications associated with the use of muscle relaxants, such as residual neuromuscular blockade, must be anticipated. The application of guideline-based approaches, including continuous neuromuscular monitoring and the application of muscle relaxant reversal agents, may significantly reduce the rate of adverse events associated with the use of muscle relaxants.

Identifiants

pubmed: 39197441
doi: 10.1055/a-2195-8785
doi:

Substances chimiques

Neuromuscular Blocking Agents 0
Neuromuscular Depolarizing Agents 0
Succinylcholine J2R869A8YF

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

494-504

Informations de copyright

Thieme. All rights reserved.

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH